Ertugliflozin was noninferior to placebo in reducing the risk for major adverse cardiovascular events -- a composite of death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke -- among type 2 diabetes patients with atherosclerotic cardiovascular disease. The findings published in The New England Journal of Medicine were based on data from 8,238 type 2 diabetes patients with ASCVD.
Study looks at CV outcomes of ertugliflozin in T2D, ASCVD
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.